stoxline Quote Chart Rank Option Currency Glossary
Apellis Pharmaceuticals, Inc. (APLS)
64.04  1.06 (1.68%)    12-07 16:00
Open: 64
High: 65.47
Volume: 1,887,771
Pre. Close: 62.98
Low: 63.3
Market Cap: 7,589(M)
Technical analysis
2023-12-07 4:18:59 PM
Short term     
Mid term     
Targets 6-month :  77.42 1-year :  90.43
Resists First :  66.28 Second :  77.42
Pivot price 53.91
Supports First :  50.77 Second :  41.18
MAs MA(5) :  63.45 MA(20) :  52.22
MA(100) :  42.12 MA(250) :  59.14
MACD MACD :  4.3 Signal :  2.7
%K %D K(14,3) :  88.2 D(3) :  91.5
RSI RSI(14): 75.2
52-week High :  94.75 Low :  19.82
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ APLS ] has closed below upper band by 13.5%. Bollinger Bands are 29.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 65.08 - 65.41 65.41 - 65.62
Low: 62.06 - 62.49 62.49 - 62.77
Close: 62.36 - 63.01 63.01 - 63.43
Company Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Headline News

Wed, 06 Dec 2023
Apellis: Focus Shifts Toward Market Share (APLS) - Seeking Alpha

Tue, 05 Dec 2023
Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch - Apellis Phar - Benzinga

Mon, 04 Dec 2023
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry - Yahoo Finance

Sun, 03 Dec 2023
APLS NOTICE : ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc ... -

Fri, 01 Dec 2023
Is Apellis Pharmaceuticals Inc (APLS) a Winner in the Healthcare Sector? - InvestorsObserver

Fri, 01 Dec 2023
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 119 (M)
Shares Float 79 (M)
Held by Insiders 13.6 (%)
Held by Institutions 96.7 (%)
Shares Short 16,140 (K)
Shares Short P.Month 18,590 (K)
Stock Financials
EPS -5.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.96
Profit Margin -222.1 %
Operating Margin -115.2 %
Return on Assets (ttm) -44.1 %
Return on Equity (ttm) -224.6 %
Qtrly Rev. Growth 400.5 %
Gross Profit (p.s.) 0.58
Sales Per Share 2.3
EBITDA (p.s.) -5.03
Qtrly Earnings Growth 0 %
Operating Cash Flow -638 (M)
Levered Free Cash Flow -425 (M)
Stock Valuations
PE Ratio -12.25
PEG Ratio -0.4
Price to Book value 32.67
Price to Sales 27.8
Price to Cash Flow -11.91
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android